Treating Acute Hypertension: Beyond Blood Pressure Control

Please Note: This CME activity has expired. You may continue to view the material for educational purposes, but this activity is no longer eligible for CME credit.

Course Objectives:
This learning program is intended for pulmonologists, cardiologists, cardiovascular and cardiothoracic surgeons, and intensivists.

Upon the completion of this activity, you should be able to:

1. Identify appropriate parenteral treatment options in the management of acute severe hypertension in the stroke and cardiac surgical patient.
2. Discuss the role of parenteral calcium-channel blockers in the management of acute stroke and acute hypertension.
3. Review and compare the adverse event profiles of parenteral antihypertensives used in the management of acute stroke and acute hypertension.
4. Discuss the consequences of inadequate blood pressure control in the acute neurological and cardiovascular care patient.

Accreditation:
Millennium CME Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Millennium CME Institute, Inc. designates this educational activity for a maximum of 1.0 Category 1 Credit toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

This activity was reviewed for relevance, accuracy of content, balance of presentation, and time required for participation by Peter J. Papadakos, MD, FCCP, FCCM; Julius D. Cheng, MD, MPH; and Joseph W. Dooley, MD.

Release Date: December 2004

Expiration Date: December 31, 2005

© 2004 Millennium CME Institute, Inc.

Faculty Disclosure:
Millennium CME Institute, Inc. endorses the Accreditation Council for Continuing Medical Education Standards for Commercial Support. Every effort has been made to encourage faculty to disclose any commercial relationships or personal benefit with companies whose products are discussed in educational presentations. Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

The faculty listed below have declared that they have no financial arrangements or affiliations with any corporate organization offering financial support or grant monies for this CME program or with any corporate organization whose product(s) will be discussed in their presentation(s):

• Julius D. Cheng, MD, MPH
• Michaeline Daboul
• Karen Doherty, PharmD
• Joseph W. Dooley, MD
• David C. Howard

The faculty listed below have declared the following arrangements and/or affiliations:

• Joseph Varon, MD, FACP, FCCP, FCCM: Speakers Bureau—ESP Pharma
• Peter J. Papadakos, MD, FCCP, FCCM: Consultant—ESP Pharma; Speakers Bureau—ESP Pharma; Stockholder—ESP Pharma

Signed Disclosure forms are on file at Millennium CME Institute, Inc.

This CME-certified monograph contains information on commercial products that is outside of current FDA-approved labeling or information on the investigational use of products not yet approved by the FDA.

Directions:
The learner should read the learning objectives and study the publication. After analyzing the material, the learner should complete the self-assessment test consisting of a series of multiple-choice questions.

Upon completing this activity as designed, described above, participants will receive a letter of credit awarding AMA/PRA Category 1 Credits six (6) weeks after receipt of the test, registration and evaluation materials.

Estimated time to complete this activity as designed is 1.0 hour.

CME Testing Options